Table 3 Top ten most significant paths, their cancer-type sign and prognosis factor according to the literature
Path | BRCA | KIRC | LUAD | Prognosis Factor |
|---|---|---|---|---|
PPAR:CD36 | DOWN | UP | DOWN | Metastatic potential and immunotherapy resistance [15,16,17], UP: poor prognosis |
Axon Guidance: CFL1 | DOWN | DOWN | DOWN | Invasion, metastasis progression, therapy resistance, DOWN: better prognosis |
Melanogenesis: TYRP1 | UP | DOWN | DOWN | Metastatic potential, DOWN: poor prognosis |
Thyroid hormone: RCAN1 | DOWN | DOWN | DOWN | Metastatic potential, treatment resistance (sunitinib) [18, 19], DOWN: poor prognosis |
Aldosterone synthesis and secretion: PDE2A | DOWN | DOWN | DOWN | Invasive and metastatic potential [20], DOWN: poor prognosis |
Aldosterone-regulated sodium reabsorption: FXYD4 | UP | DOWN | DOWN | Recurrence-free survival following surgery [21], DOWN: poor prognosis |
Aldosterone-regulated sodium reabsorption: SCNN1A | DOWN | DOWN | DOWN | Proliferation, migration, poor prognosis [22, 23], DOWN: better prognosis |
Aldosterone-regulated sodium reabsorption: KCNJ1 | DOWN | DOWN | DOWN | Prognostic factor of patient’s survival, Metastatic potential [24], DOWN: worse prognosis |
Salivary secretion: RYR3 | DOWN | DOWN | DOWN | Unfavorable prognosis and upcoming malignant conversion [25], DOWN: poor prognosis |
Proteoglycans in cancer: CTNNB1 | DOWN | DOWN | DOWN | Unfavorable outcomes, metastasis potential, immunotherapies resistance [26, 27], DOWN: better prognosis |